Table 4. HRs and 95% CIs for subsequent cancer in relation to type of treatment.
|
Type of treatment
|
||
|---|---|---|
| Site | Radiotherapy | Hormone therapy |
| Uterus | ||
| Pyrsa | 41 554 | 26 866 |
| nb | 22 | 34 |
| HRc | 0.83 | 2.97 |
| CI | 0.50–1.37 | 1.84–4.80 |
| Breast | ||
| All | ||
| Pyrsa | 34 105 | 22 834 |
| nb | 145 | 120 |
| HRc | 0.73 | 1.01 |
| CI | 0.60–0.89 | 0.82–1.25 |
| Ipsilateral | ||
| Pyrsa | 27 803 | 19 387 |
| nb | 49 | 65 |
| HRc | 0.40 | 1.20 |
| CI | 0.29–0.55 | 0.89–1.61 |
| Contralateral | ||
| Pyrsa | 40 408 | 26 281 |
| nb | 96 | 55 |
| HRc | 1.07 | 0.85 |
| CI | 0.84–1.37 | 0.63–1.15 |
CI=confidence interval; HR=hazard ratio; Pyrs=person-years.
a
Total person-years in group receiving treatment of specified type.
b
Number of occurrences of subsequent cancer in group receiving treatment.
c
HR for treatment recorded vs not recorded, adjusted for 5-year age group and other treatment mode.